Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1007/s00393-016-0255-3
Published Online: 2017-01-13
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weber, S.
Pongratz, G.
Schneider, M.
Brinks, R.
License valid from 2017-01-13